Launched in 2020, Kurome® Therapeutics is developing therapies that target cancer cells that have co-opted immune signaling pathways in order to avoid destruction by traditional therapeutic agents and subvert adaptive resistance mechanisms.
Jan Rosenbaum
Daniel Starczynowski